RELATIVE IMPACT OF VARIOUS SOURCES OF PHARMACOKINETIC AND PHARMACODYNAMIC VARIABILITY ON WARFARIN RESPONSE by Gannu, Shashikanth
University of Rhode Island 
DigitalCommons@URI 
Open Access Master's Theses 
2000 
RELATIVE IMPACT OF VARIOUS SOURCES OF 
PHARMACOKINETIC AND PHARMACODYNAMIC VARIABILITY ON 
WARFARIN RESPONSE 
Shashikanth Gannu 
University of Rhode Island 
Follow this and additional works at: https://digitalcommons.uri.edu/theses 
Recommended Citation 
Gannu, Shashikanth, "RELATIVE IMPACT OF VARIOUS SOURCES OF PHARMACOKINETIC AND 
PHARMACODYNAMIC VARIABILITY ON WARFARIN RESPONSE" (2000). Open Access Master's Theses. 
Paper 250. 
https://digitalcommons.uri.edu/theses/250 
This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion 
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, 
please contact digitalcommons@etal.uri.edu. 
I ( 
( 
RELATIVE IMP ACT OF VARIO US SOURCES OF PHARMA CO KINETIC AND 
PHARMACODYNAMIC VARIABILITY ON WARF ARIN RESPONSE 
BY 
SHASHIKANTH GANNU 
A THESIS SUBMITTED IN PARTIAL FULFILMENT OF THE 
REQIDREMENTS FOR THE DEGREE OF 
MASTER OF SCIENCE 
IN 
APPLIED PHARMACEUTICAL SCIENCES 
UNIVERSITY OF RHODE ISLAND 
2000 
MASTER OF SCIENCE THESIS 
( 
OF 
SHASIDKANTH GANNU 
APPROVED: 
Thesis Committee 
Major Professor _..._fJ""---041_..__--'V __ {0---=-:.0-=Wk~..:.......;:;;.~-....;....i<.......L.....L--
( 
F THE GRADUATE SCHOOL 
UNIVERSITY OF RHODE ISLAND 
2000 
( 
ABSTRACT 
Warfarin is widely used oral anticoagulant and its pharrnacokinetic (PK) and 
pharrnacodynamic (PD) properties have been extensively studied. It has a narrow 
therapeutic index and displays poor quality of treatment due to its complex pharmacology 
and wide inter and intraindividual variability in the dose-response relationship. 
This study developed an integrated PK-PD model using STELLA® to describe the dose-
concentration-effect relationship for warfarin. This model used previously reported 
population PK and PD models and parameter values to generate dose-response data. A 
one compartment stereo-specific semi-physiological PK model with zero-order drug 
input was linked to an indirect PD model describing the anticoagulant effect. The indirect 
PD model consisted of two components: (i) the plasma concentration of S-enantiomer of 
warfarin (Cs) was related to synthesis of prothrombin complex activity (PCA) described 
by sigmoid Imax model (ii) conversion of PCA to prothrombin time ratio (PTR), which is 
further standardized in terms of INR. The model was used to study the manner in which 
the interindividual variability in fundamental PK parameters (intrinsic clearance, protein 
binding affinity constant and protein concentration), PD parameters (potency and 
sigmoidicity) and intraindividual variability in dose affect warfarin response. For each 
condition of interindividual variability studied, 100 sets of PK and PD response data were 
collected and % coefficient of variation (CV) was calculated. For each condition of 
intraindividual variability studied, 2000 data sets of PD response were collected and % 
CV was calculated. 
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( For the model used in this study, variability in the response to warfarin was least sensitive 
to interindividual variability in protein binding affinity constant of S-warfarin (Ka_s), 
protein concentration (P) & sigmoidicity (Y) and also to intraindividual variability in 
dose. The PK and PD response was found to be most sensitive to interindividual 
variability in intrinsic clearance of S-enantiomer (CLint_s) and potency (IC5o) parameters. 
Clinically, these parameters are important and their variability in population must be 
taken into account in order to optimize the dose and use the drug effectively and safely. 
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1. INTRODUCTION 
The relationship between dose and response is the cornerstone of drug therapy. 
Traditional PK models alone have limited applicability in understanding complete dose-
response relationship for drugs that do not have direct linear relationship between drug 
concentration and therapeutic effect. For such drugs, thorough understanding of all of the 
individual processes involved from the time the dose is administered to the appearance of 
the clinically observed effect is very important. Overall, the intensity and duration of 
response to a given dose of a therapeutic drug can be considered as a function of two 
sequential phases: PK phase and PD phase. The PK phase describes the drug 
concentration-time course m body fluids (often plasma/ serum) resulting from 
administration of a certain dose of a drug. The PD phase, on the other hand, relates 
observed effect to the concentration of drug at the "effect site". 
1.1. Pharmacokinetic Models: 
PK models, which incorporate the rate processes of distribution, metabolism and 
elimination as well as absorption in the case of orally administered drugs, are derived 
from concentration time data. The models can then be used to observe the system under a 
variety of conditions. Often the PK phase is linear and as a result the dose concentration 
relationship is fairly predictable. Critical PK parameters that are used to describe the PK 
processes include volume of distribution and clearance. For orally administered drugs, 
additional PK parameters include absorption rate and bioavailability. The number of 
parameters required to describe the dose-concentration relationship depends on the 
complexity of the process and on the route of administration. 
Over the last two decades the knowledge of pharmacokinetics has increased greatly and a 
variety of mathematical models and software have been successfully developed. The 
pharmacokinetics of most of the drugs and the factors influencing the PK processes are 
well understood and documented. 
1.2. Pharmacodynamic Models: 
PD models are used to characterize the relationship between drug concentrations at the 
site of action and the pharmacological effect (I) and are used to develop mathematical 
expressions to describe the drug response as a function of the concentration time profile. 
Although the concentration at the receptor site drives the response, owing to the 
difficulties associated with measuring this value, plasma concentrations are usually used 
for PD models in vivo. Critical PD parameters include efficacy (Emaxllmax), potency 
(EC50/IC50) and sigmoidicity (Y). The efficacy represents the maximum effect that occurs 
when all the receptors are occupied. The potency is the concentration at 50% of the 
maximum effect and Y is the number of drug molecules bound to each receptor and it 
determines the steepness of the concentration-effect relationship. If the drug has 
stimulatory action the PD parameters are Emax and EC5o and if the drug has inhibitory 
action, Imax and IC5o are used to represent efficacy and potency respectively. When the 
PK steady-state conditions exist and the pharmacological effect is easily measured, 
concentration-effect relationships can be described by simple PD models such as fixed 
effect model, linear model, log-linear model, Emax-model, and sigmoid Emax-model <1>. 
The selection of model basically depends on many factors such as (a) the drug used (b) 
2 
( the response to be measured ( c) the effect observed after administration of drug and of 
placebo (d) the degree of linearity in the effect-concentration curve (e) potential for 
achieving the maximum possible response. However, the non-linear Emax and sigmoid 
Emax models are very commonly used to describe the PDs of many drugs. The sigmoid 
Emax model is a modification of the Emax model, which accounts for the probability that 
more than one drug molecule binds to each receptor by using the term sigmoidicity (f). 
The sigmoid Emax model is derived from the Hill equation <2>. In some cases, additional 
components are required to accommodate distribution lag times and/or indirect drug 
effects, which often complicate the concentration-response relationship. In the case of a 
distributional delay (3>, plasma concentration Vs effect plots indicate pronounced 
hysteresis. Such relationship can be simplified by considering hypothetical effect 
compartment to account for the time lag between concentration and response (t ,4>, and 
using steady-state conditions. Owing to the complex and non-linear nature of the plasma 
concentration-effect relationships, it is often difficult to predict how the system may 
behave under a variety of situations. Thus, simulation studies can be very valuable. 
The PDs of relatively few drugs has been extensively studied due to the difficulty in 
measuring clinically relevant responses. In the absence of PD information it is difficult to 
appreciate and understand the impact of altered PKs on the drug response. 
1.3. Combined Pharmacokinetic-Pharmacodynamic models to understand the dose-
response relationships: 
3 
( In understanding dose-response relationships, an integrated approach involving combined 
pharmacokinetic and pharmacodynamic modeling has proved tremendously helpful <5•6•1>. 
The objective for PK-PD modeling is to link PK and PD phases of the drug to establish 
and evaluate dose-concentration-response relationships and subsequently describe and 
predict the effect-time courses resulting from given dose of drug. In general, PK-PD 
modeling based on the underlying physiological process should be preferred whenever 
possible <5>. This approach has provided significant insight into the pharmacology of 
various drugs under conditions of normal and abnormal physiology. Furthermore, to 
characterize and appropriately describe the time course of drug action under non steady-
state conditions, PKs and PDs of the drug have to be adequately linked to predict dose-
concentration relationship and concentration-effect relationship. This link can be 
established, when the plasma concentration is substituted for concentration in PD 
equations with an assumption that the concentration at the site of action is in equilibrium 
with plasma. This assumption may be valid, if the drug effect is direct, receptor site 
rapidly equilibrates with plasma and the drug-receptor interaction in relation to the 
response occurs rapidly. 
The direct correlation of pharmacological response to drug concentration is not always 
possible with all drugs. Sometimes intermediate steps are involved in the mechanism of 
action of the drug that is more complex than is assumed in the model. For example, dose-
response relationships can be complicated when the drug action is indirect and/or 
irreversible. Four basic physiologic indirect response models proposed by Jusko et al. 
may be used in PK-PD modeling to describe the pharmacodynamics of drugs that have 
4 
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indirect mechanisms such as inhibition/stimulation of the production or degradation of 
endogenous substances/mediators, which control the measured response cs, 9• IO) . These PD 
models when coupled with the PK models of the drug help in simplifying the relationship 
between the dose administered and the clinically observed response. For example, 
warfarin (anticoagulant) exerts an indirect action and the resultant delay in response 
makes a direct correlation of the anticoagulant activity to the plasma drug concentration 
impossible. Therefore, plasma warfarin level is correlated with inhibition of the 
prothrombin complex production rate, which is then linked to the pharmacological 
response (anticoagulation). The application of PK-PD modeling to understand dose-
response relationship in the case of warfarin is described in detail in the following 
sections of this thesis. 
1.4. Sources of Variability 
Biological variability is an inherent feature of drug action. Variability in a response arises 
in drug therapy when a standard dose or dosing regimen evokes differing responses in 
various individuals (referred to as interindividual variability) or in a given individual at 
different times (referred to as intraindividual variability). However, interindividual 
variability was identified to be major source of variability for many drugs Cl I). 
Intra and interindividual variability in the dose response relationship can arise from two 
sources: PK variability and PD variability. Clinically, PK variability commonly arises 
from variability in the PK parameters describing the rate and extent of absorption, 
distribution, metabolism, and elimination of drugs. Some drugs show greater 
5 
pharmacokinetic variability than others do. Variability in the PK characteristics of drug is 
well recognized and understood due to the ease of monitoring and control of therapeutic 
plasma concentrations. But, little is known about PD variability due to the difficulty of 
measuring clinically relevant responses for most drugs and limited research activity in 
this field <11 >. The other reason for poor understanding of PD variability is because of 
difficulty in distinguishing between PD and PK variability. For example, if a certain 
pharmacologic effects arises, wholly or in part, from a minor metabolite of a drug, then a 
twofold or threefold increase in the formation of that metabolite could cause a substantial 
increase in pharmacologic effect without any apparent change in the drug's PKs. The 
increased pharmacological effect may be interpreted as due to PD rather than PK 
variability if the role of the quantitatively minor metabolite has not been recognized <12>. 
The magnitude of variability in the PK and PD parameters may be of varying amounts 
depending on the drug and the pathological condition of the patient. Over the last decade 
enormous work have been done to understand PK and PD variability and the factors 
influencing this variability. Factors such as age <3• 13• 14>, gender <3• 13• 15>, disease state, 
nutrition, genetics, environment, and concurrent drug therapy <6• 16> may affect the 
patient's physiologic functions and lead to variation in the pharmacokinetic and/or 
pharmacodynamic parameters. 
The interindividual differences in the relationship between drug plasma concentration and 
pharmacological effect intensity have been reported to be mainly due to various factors. 
These factors include: (i) receptor density and affinity (ii) the formation and elimination 
kinetics of endogenous ligands (iii) postreceptor transduction processes (iv) homeostatic 
6 
( responses and (v) the kinetic characteristics of transporters involved in drug transfer 
between fluids of distribution and the biophase <11 >. Usually PD variability is more 
pronounced than PK variability. Mandema et al. reported large interindividual PD 
variability in response as compared to interindividual PK variability in the case of 
ketoro lac < 1 7>. 
1.5. Warfarin 
Warfarin, the most commonly used anticoagulant, is an example of a drug that displays 
wide-variability in the dose-response relationship in the population (6, 7' 18-22• 23>. Since 
both sub-therapeutic and large doses are associated with serious clinical consequences 
<
24>, the PK and PD of warfarin have been extensively studied. These studies have been 
conducted in order to provide insight into dose optimization and identification of factors 
that influence dose-response relationship. Additionally, since the effect of warfarin is 
easily measured, there is much information in the literature on pharmacodynamics of 
warfarin. 
Warfarin is administered clinically as a racemic mixture of two enantiomers, R- and S-
warfarin. The disposition and pharmacological action of the both the enantiomers are 
qualitatively similar but quantitatively quite different <25>. The differences in the 
anticoagulant activities and metabolism of the S- and R- isomers of warfarin are very 
large. As a result, it is necessary to consider these isomers separately in PK & PD model 
for warfarin. 
7 
( 
1.5.1. Pharmacokinetics 
The pharmacokinetics of warfarin has been extensively studied, and several reviews of 
warfarin pharmacokinetics have been published <2, 21 ' 26' 21>. Warfarin is rapidly and 
completely absorbed from the gastrointestinal tract. Warfarin does not exhibit dose 
dependency in the rate or extent of absorption, and enantiomer specific differences in 
absorption patterns have not been reported. Warfarin is highly plasma protein bound drug 
and binds to albumin at site I. The bound fraction of racemic warfarin ranged from 97.4 
to 99.9% under normal physiological conditions (6, 28>. In early 1975, Yacobi et al 
demonstrated significant intersubject variability in the extent of protein binding at 
therapeutic concentrations; intrasubject variability was much less substantial <29>. 
Variations in albumin concentrations in plasma occur as result of altered synthesis, loss, 
or a shift of albumin from the intravascular to extravascular spaces. Physiologic 
conditions such as age, pregnancy, and nutritional status cause decrease in albumin 
concentration <30>. Pathologic conditions include renal disease, hepatic disease, acute 
myocardial infraction, cancer, sever bum injury, diabetes mellitus, thyroid disease, and 
cystic fibrosis lead to decreased plasma protein binding due to altered protein 
concentrations, or qualitative changes in protein molecules <30>. Concurrent administration 
of warfarin with other highly protein bound drugs having affinity to site I on albumin 
may lead to changes in binding of warfarin. The principal route of warfarin elimination is 
hepatic metabolism and renal excretion was reported to be very negligible <31 >. The 
metabolic elimination of the pharmacologically more potent S-enantiomer is mediated by 
cytochrome P450 CYP2C9 isoform which steroselectively converts S-warfarin to the 
inactive phenolic metabolite, S-7-hydroxywarfarin. The rate of elimination of the two 
8 
( isomers differs substantially. Warfarin undergoes restrictive hepatic clearance <
32>. Thus 
its clearance is approximated by the following equation: 
Where, 
CLtt is the Hepatic clearance of warfarin; 
CLint is the Intrinsic clearance of warfarin; and 
fu is the fraction of warfarin unbound to plasma proteins; 
(1) 
It can be seen from equation (1), an increase in "free" fraction in an individual would 
lead to a substantial increase in hepatic clearance and thus total body clearance. The 
variations in intrinsic clearance of warfarin are usually associated to interindividual 
differences in the activity of the drug metabolizing enzyme systems due to genetic and 
environmental effects. The hepatic metabolism was reported to be the major determinant 
of intrasubject variability in the warfarin dose-concentration-response relationship. 
1.5.2. Pharmacodynamics 
Unlike the direct concentration-effect relationships identified for most drugs, the 
relationship between warfarin's anticoagulant effect and the drug's concentration in 
serum or plasma is nonlinear, complex and indirect. The anticoagulant action of warfarin 
is mediated by inhibition of vitamin K reductase linked to the vitamin-K dependent 
carboxylation of glutamic acid residues on certain coagulation proteins like prothrombin, 
clotting factors II, VII, IX, X and protein C <33). The overall effect can be characterized in 
terms of the degree of inhibition of the synthesis rate of prothrombin-complex activity 
9 
( (PCA). The reduction in the activity of these clotting factors results in a prolongation of 
clotting time, an effect easily measured clinically. 
Warfarin is administered as a mixture of R- and S- enantiomer. However, the 
anticoagulant activity of the S-enantiomer has been reported to be 3 to 6 times as greater 
as that of the R-enantiomer <34>_ The pharmacodynamics of warfarin have been described 
using a mechanism-based indirect model <2• 10• 33>_ This consists of a sub-model for 
synthesis and degradation of clotting factors, and the inhibitory action of warfarin on 
clotting factors synthesis. Changes in the amount of clotting factors alter the PCA, which 
can be clinically assessed using prothrombin clotting time (PT). Owing to the 
dependency of the PT on the particular thromboplastin used in the test an additional 
thromboplastin-specific parameter, International Sensitivity Index (ISI), is required to 
relate a thromboplastin dependent PT to the standardized international normalized ratio 
(INR) <35• 36• 37>. Although the INR system is unreliable during the initiation of warfarin 
therapy, it does provide an advantage over the reporting of the results as PT ratio <36• 38>. 
Thomas et al. indicated that oral anticoagulant therapy monitored with the INR is 
associated with lower bleeding complications than therapy monitored with the PT ratio, 
and the rate ofthromboembolic events using the INR is acceptably low <39>_ 
Factors that have been reported to influence sensitivity to warfarin include (i) disease 
conditions: congestive heart failure <25>, thyroid disease <40> (ii) age <41 > (iii) hepatic 
insufficiency <42> (iv) differences in the hemostatic response to given concentrations of 
warfarin and (v) concomitant administration of other drugs <20>. Factors that influence 
JO 
( warfarin resistance include (i) Patient non-compliance (ii) Excessive intake of vitamin K 
(iii) Co-administration with other drugs that induces cytochrome P450 2C9 enzyme 
system and (vi) hereditary resistance which may require increased doses of warfarin <43• 44• 
45) 
Several approaches have been proposed in the literature to describe the anticoagulant 
response of warfarin using a combined pharmacokinetic-pharmacodynamic model (2) . 
However, previous attempts have not considered the warfarin anticoagulant response in 
terms of INR. In the present study, INR component was considered in the integrated PK-
PD model to report the pharmacodynamic effects of warfarin. 
The effect of variability in PK parameters and PD parameters play an important role in 
causing the variability in therapeutic response among population. Therefore, these 
simulation studies were conducted to compare the individual and combined effect of PK 
and/or PD parameters of warfarin on PK response data from a one compartment model 
with zero order absorption and PD response arising from an indirect sigmoid Imax model. 
The objectives ofthis study include: 
I. To create an integrated PK-PD model for warfarin that takes into account individual 
enantiomers of warfarin. The model developed in STELLA® use average population 
values of the parameters from previous investigations (6, 7)_ PK model includes a sub-
mode! for clearance based on well-stirred venous equilibrium component. This sub-
mode! helps in understanding the effect of parameters such as fraction of S-warfarin 
11 
( bound to plasma proteins and intrinsi9 clearance of S-enantiomer (CLint_s) on plasma 
concentration of S-enantiomer (Cs) and anticoagulant effect of warfarin in terms of 
INR. 
2. Perform computer simulations: 
(i). To evaluate and compare the manner in which different sources of variability in 
PK parameters such as CLint_s, protein binding affinity constant CKa_s) and plasma 
albumin concentration (P) and PD parameters such as IC5o and Y affect the dose-
response relationship of warfarin. 
(ii). To investigate the relative impact of intraindividual variability in dose on Cs, and 
INR. 
All the simulations were performed using computerized integrated PK-PD model. 
12 
( 2. METHODOLOGY 
The integrated PK-PD model describing the complete dose-response relationship for 
warfarin was constructed in STELLA® (High Performance Systems, Hanover, NH). This 
model was used throughout the study. 
2.1. Pharmacokinetic Model 
A one-compartment stereo-specific semi-physiological pharmacokinetic model, which 
adequately describes the warfarin dose-concentration relationship, was used (6). Hignite 
<
46
> and Chan <6> reported that the anticoagulant activities and metabolism of warfarin 
enantiomers are different in many aspects. For these reasons, the PK model in this study 
took into consideration the individual isomers of warfarin as separate drugs. Constant, 
zero order oral administration was used in all the simulations. The bioavailability of 
warfarin was assumed to be 100% <2> and the dose was assumed to be absorbed rapidly 
and completely <42> at a constant rate over a 24 hour dosing interval. Zero order input was 
assumed in all the simulations so it would facilitate the understanding of different 
sensitivity of the warfarin response to various different factors. 
In 1993, Pitsiu et al. performed a population PK and PD study of warfarin in 48 normal, 
healthy young volunteers <7>. Another population study was conducted by Chan et al. in 
1994 <6>. The population PK and PD parameter values reported by these studies were used 
in the present investigation. These parameters were chosen due to the following reasons: 
the study represented an integrated PK-PD analysis and thus both PK and PD parameters 
were derived in the same analysis; PK and PD data were available on both S- and R-
13 
( enantiomer of warfarin and since these isomers were reported to display different 
pharmacokinetics and pharmacodynamics <46• 48>, it was considered that each isomer 
should be represented individually in the model; a true population approach using 
NONMEM was used and the estimates were also in agreement with those reported in the 
previous studies <49>, 
The primary route of warfarin elimination was reported as hepatic metabolism <50>. 
Hepatic clearance was calculated using the well-stirred venous equilibrium model <32> 
with the equation. 
Where, 
CLH=E * Q 
E = (fu * CLint) I (Q + fu * CLint) 
CLH is the hepatic clearance of warfarin; 
Eis the extraction ratio; 
Q is the hepatic plasma flow, 40.5 L/h <51 >; 
fu is the fraction of drug unbound to plasma proteins; and 
CLint is the intrinsic hepatic clearance of warfarin 
(2) and 
(3) 
W arfarin was assumed to undergo first order elimination <7>. Mean population PK 
parameter values obtained from the warfarin literature of Pitsiu et al. were used. The 
parameter values were well in agreement with other investigations <6>. First order 
elimination rate constants of S- and R- enantiomer used in the model were 0.0254 and 
0.0193 h-1 respectively. The terminal half-lives of S- and R- enantiomer were calculated 
to be 27.3 and 35.9 hours respectively which means it takes about a week to reach steady-
14 
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state conditions. The volume of distribution was 11.8 and 10.5 L for S- and R- warfarin 
enantiomers respectively. The unbound fraction (fu) for S- and R- enantiomer of warfarin 
was assumed to be 0.51 and 0.62 % respectively <6>. 
Finally, intrinsic hepatic clearance of S- and R- enantiomer were calculated and set at 
59.21 and 32.85 L/h respectively. 
Effect of Protein Binding: 
Concentration-dependent protein binding occurs with highly protein bound drugs such as 
warfarin. The unbound fraction of warfarin can be mathematically described as 
fu = 1 I [l +Ka * P] (4) 
Where, 
Ka is the affinity constant for protein binding; and 
P is the concentration of albumin plasma protein (6.5 * 104 Molar); 
The values of affinity constants for S- and R- enantiomer were calculated using the above 
equation and were initially set at 3.0 * 105 and 2.466 * 105 Molar-1 respectively. 
Initially, the amounts of both the warfarin enantiomers in the model were set to steady 
state levels. Thus, the combined and individual enantiomer steady-state plasma 
concentrations were expressed using equation 
Where, 
CPss =DI (CL* 't) 
CPss represents the steady-state concentration of warfarin; 
D is the dose of warfarin; 
15 
(5) 
CL represents the total body clearance; and 
i: is the dosing interval; 
2.2. Pharmacodynamic Model 
The simple linear PD models that were usually used to describe the direct relationship 
between plasma concentration and the response are inadequate to describe the 
pharmacodynamics of warfarin. As described earlier, PDs of warfarin is best described 
using an indirect inhibitory model in which, warfarin concentrations are related to 
clotting factor synthesis but only indirectly related to the observed therapeutic effect 
(INR). This indirect PD model consists of two sub-components: 
(i). Relationship between warfarin concentration and PCA/PT 
(ii). Conversion of PCA to INR 
2.2.1. Relationship between warfarin concentration and PCA/PT 
In this sub-component of the PD model the plasma concentration of S- enantiomer was 
related to the PCA. Both synthesis and degradation of the clotting factors determine the 
hypoprothrombinemic effect, yet warfarin will only affect synthesis. A physiologic effect 
model describing the direct relationship between warfarin inhibition of epoxide reductase 
and clotting factor synthesis as proposed by Nagashima et al. <52> was used. The 
prothrombin complex activity in the plasma represents the net effect of the synthesis of 
various clotting factors such as II, VII, IX, X and their normal degradation. This model 
assumes time course of PCA after warfarin administration as a function of rate of 
16 
synthesis and degradation of clotting factors. This relationship can be mathematically 
described as: 
Where, 
dPCA/dt = Rs - Ri 
Rs is the Rate of PCA synthesis; and 
Ri is the rate of PCA degradation; 
(6) 
The Rs and Ri values in the equation are expressed in terms of per cent of normal 
activity. The rate of PCA degradation was calculated from it's first order rate of 
degradation (Kct) and can be expressed as: 
Ri = Kct * PCA (7) 
The effect of warfarin on PCA synthesis can be expressed in terms of its fractional effect 
Rs = Kct * PCAnormaI * l(t) (8) 
Under normal circumstances the system is assumed to be at steady state and PCA has its 
maximum value (100 %) 
Rs = Kct * 100% (9) 
A sigmoid Imax model <2• IO) was used to relate warfarin concentrations to the inhibitory 
action on PCA synthesis rate. Previous investigations <6• 7> indicated that R-enantiomer 
have negligible effect on clotting factor activity that it can be neglected in the PD model. 
Therefore, in this study, it was assumed that only S-enantiomer had pharmacological 
activity and its concentration was linked to the PD model. The degree of inhibition of 
clotting factor synthesis by S-enantiomer is expressed as: 
l(t) = [1 - (C/ I (ICsor + C/))] 
Which may be simplified and rewritten as 
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( 
Where, 
(11) 
I(t) is the inhibitory function of warfarin concentration that predicts the synthesis 
rate as a percentage of the baseline value; 
Cs is the plasma concentration of S-warfarin; 
IC5o is the plasma concentration of S-warfarin that produces 50% inhibition of 
clotting factor synthesis; and 
Y is the sigmoidicity describing the steepness of the concentration-effect curve; 
As indicated before the values reported for warfarin population analysis by Pitsiu et al. <7> 
were used for the PD and physiological model parameters. First order rate of degradation, 
Kct was set at 0.094 h-1, and the half-life of Kct was calculated to be 7.4 hours. The values 
ofIC50 and n were initially set in the model as 0.394 and 1.0 respectively (7)_ 
2.2.2. Conversion of PCA to INR 
When monitoring treatment with warfarin, it is common practice to assess PCA by 
determining PT and the therapeutic range is usually specified in terms of the prothrombin 
time ratio (PTR). The PTR is the patient's PT divided by the laboratory's control or 
normal PT. By using the PTR instead of PT alone, part of the technical variation in the 
PT test is eliminated, since the ratio is unaffected if both the patient's and the normal PT 
vary in the same proportion. The regression equation described by Chan et al. <6> and 
obtained from serial dilutions of normal plasma was used to convert PCA to PTR 
PTR = (426 + PCA * 7.75) I (PCA * 12) (12) 
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However, still systematic variation may be observed in PTR determinations due to the 
considerable variability in the sensitivities of thromboplastin from different species, 
manufacturer to manufacturer and lot to lot. As a consequence of the variability in 
response of different thromboplastin reagents, PTR results are not comparable from 
laboratory to laboratory without knowing the sensitivity of the thromboplastin. As a 
result this variation could produce potential problems for anticoagulation control. 
The need for standardizing the measurement of PTRs has long been recognized <53>. In 
early 1980, the term INR was introduced to standardized the PTR by adjusting for 
variability in thromboplastins with different sensitivities. Finally, the World Health 
Organization has urged that all medical staff and health auxiliaries involved in controlling 
anticoagulant treatment in patients should use the INR. INR system is based on 
International Sensitivity Index (ISI) values derived from the plasma of patients stabilized 
on a regimen of anticoagulant treatment for at least 6 weeks. The expression used to 
convert PTR to INR can be described as <37> 
INR = [PTR]1s1 (13) 
The INR would be equal to PTR if a thromboplastin with an ISI of unity were used in the 
test. In this study, PTR was converted to INR using ISI of 2.2 since this is the estimated 
ISI of the thromboplastin used by Chan et al <6• 54>. 
Anticoagulation provides a striking benefit for patients whose treatment is conducted 
within the recommended range of the INR, 2.0 to 3.0. In this study this range for INR 
was considered as therapeutic range for reporting final anticoagulant response. 
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2.3. Pharmacostatistical Model 
2.3.1. Interindividual Variability Model 
Interindividual variability in PK parameters (intrinsic clearance and protein binding 
affinity constant for S-warfarin) and PD parameters (potency and sigmoidicity) were 
modeled using the proportional error model <55) as follows: 
(14) 
Where 
Sj represents the estimate for a PK or PD parameter in the jth individual ; 
8 m represents population mean of the PK or PD parameter; and 
llej is normally distributed random variable with zero mean and variance ro2 for 
variability in PK and PD parameter; 
The effect of 6 levels 10, 20, 30, 40, 50, and 60% CV of interindividual variability in 
each parameter was investigated. The model use "sample and hold" set up in STELLA® 
for each PK and PD parameter as shown in Figure 1 b, 1 c, 1 d & 1 e such that the 
interindividual variability model cause each parameter to vary every 480 hours. 
2.3.2. Intraindividual Variability Model 
Intraindividual variability in dose was modeled using the proportional error model <55) as 
follows: 
(15) 
Where 
Dij is the administered dose for the jth individual at time i; 
Di is the model predicted dose in /h individual at time i; 
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( Eij is normally distributed random variable with zero mean and variance cr
2
; and 
er, the coefficient of variation of the variability was set to 3%, 6% and 10% CV 
In this model, intraindividual variability was assumed to cause the value of dose to 
deviate from model predicted value by an amount that is proportional to the value of the 
dose. This model use sample and hold set up as shown in Figure lg such that 
intraindividual variability caused the dose to vary with new dose after every 24 hours. 
2.4. Simulations 
The impact of variability in the dose, PK and PD parameters on response variables was 
studied using zero order drug input under steady-state conditions. When no variability 
was given to the model parameters, the dose of 7mg and 9mg resulted INR value at the 
lower end (2.2) and higher end (2.7) of therapeutic range, respectively. Owing to the non-
linear relationship between the dose administered and observed INR, simulations studies 
for intraindividual variability in dose were carried out at the low and high end of the 
therapeutic range using daily doses of 7 mg and 9mg, respectively. 
For each set of model parameters in the PK variability studies, 100 replications of 
response data (Cs and INR) were generated at 480 hour time point (under steady-state 
conditions). For each set of model parameters in PD variability studies, 100 replications 
of response data (INR) were generated at 480 hour time point (under steady-state 
conditions). For the intraindividual dose variability studies, the response (Cs and INR) 
was measured at every 24 hours over a 20 day period and 100 replications were 
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performed giving a total of 2000 responses. In all the simulation runs the response data 
was generated by numerical integration after every 0.01 h. 
INR value within 2.0 to 3.0 was considered as therapeutic event. Any INR value < 2.0 
was considered as sub-therapeutic event and any value >3.0 as event causing significant 
risk of hemorrhage. 
2.5. Data Treatment 
Response data generated from the simulations as described above were imported from 
STELLA® to a Microsoft Excel worksheet. The mean, standard deviation (SD), and thus 
% coefficient of variance (CV) in response was determined for each of the 100 data sets 
associated with a given experimental condition. The response values beyond 2.5*SD 
were excluded from the analysis. 
2.6. Statistical Analysis Using ANOV A: 
ANOVA design provides greater opportunity to identify the significant parameters and 
analyze the PK and PD interactions at different treatment combinations. In this study, 24 
full factorial design was used to identify the individual PK parameters, PD parameters 
and the combination of PK & PD parameters that have significant effect on the variability 
in warfarin response (INR). The general linear model used for the ANOVA analysis was: 
Y = Po+P1X1+P2X2+P3X3+P4N+P12X1X2+P23X2X3+P34X3N+P14X1N+P13X1X3+ 
P24X2N+P123X1X2X3+P234X2X3N+P134X1X3N+P1234X1X2X3N+E 
Where: 
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X1 = CLint_s; X2 = Ka_s; X3 = ICso; Xi= Y; 
X1, X2, X3 and Xi are each of the independent variables; 
X1X2, X2X3, X3Xi, X1Xi, X1X3 and X2Xi are the two-way interactions; 
X1X2X3, X2X3Xi and X1X3Xi are the three-way interactions; 
X1X2X3Xi is the four-way interaction; 
13 0 is the overall mean; 
13 1, 132, 133, 134 are the coefficients of factor effects; 
1312, 1323, 1334, 1313, 13 14, 1324 are the coefficients of two-way interaction effects; 
13123, 13 234, 13 134 are the coefficients of three-way interaction effects; 
131234 is the coefficient of four-way interaction effect; and 
8 is the error variable; 
The experimental design for ANOVA studies is shown in Table 4. Table 4 lists all the 16 
experiments required in a 24 full factorial design. The four independent variables (CLint_s, 
Ka_s, ICso and Y) were set at two levels each (60% CV and 30% CV). ANOVA was used 
to determine the significance of each of the four independent variables, two-way, three-
way interactions and four-way interactions. ANOVA procedures on the response 
parameter (INR) were performed using Minitab ®software package. 
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3.1. Variability in PK parameters: 
3.1.1. Effect of variability in CLint_s: 
The effect of 6 levels of interindividual variability (10, 20, 30, 40, 50 and 60 % CV) in 
CLint_s on variability in steady state PK response (Cs) and PD response (INR) was studied 
with 7 mg warfarin dose. The model was set to steady state conditions when variability 
was added. Table 2 and 3 show the results for variability in Cs and INR, respectively. 
The manner in which variability in CLint_S affects Cs and INR are shown in Figure 2 and 
3, respectively. There was an approximately linear relationship between the variability in 
CLint_s and the PK & PD responses up to about 40 % CV in CLint_S· Of these responses 
up to 30 % CV, the variability in CLint_s produced approximately equal variability in Cs 
and slightly less in INR. At 50 % or greater variability in CLint_s, the variability in Cs and 
INR was found to increase by greater than two fold of that considered in CLint_S· From 
equation 2, it can be observed that the hepatic clearance becomes more sensitive as 
CLint_s increases and therefore we see higher variability in PK and PD responses. At the 
maximum variability (60 % CV) in CLint_s, the observed variability in INR and Cs was 
approximately 120 and 163 %, respectively. 
3.1.2. Effect of interindividual variability in Ka_sl[P]: 
From equation 4, it can be seen that the effect of Ka_s and [P] on fu are similar. In 
simulations, it was found that similar variability in Ka_s and [P] produce same variability 
on response values (data not shown). As a result, in this study the effect of variability in 
only one of these parameters was studied. 
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Computer simulations were carried with the fixed dose of 7 mg warfarin and dosing 
interval of 24 hours. The effect of interindividual variability in the Ka_s was translated to 
changes in steady state Cs and INR (at 480 hours). The results of these simulations are 
shown in Table 2 and 3. Figure 2 & 3 represents the effect of the variability in Ka_s as the 
function of % CV in PK and PD responses. The relationship between the variability in 
Ka_s and the variability in drug's PK and PD responses were found to be linear. Over the 
entire range of variability studied, the variability in Cs and INR was found to be less than 
that considered in Ka_S· As seen in Figure 2 and 3, the variability in the Ka_s produced 
small changes in steady state Cs and INR compared to that due to the variability in 
CLint_S· For example, with 60 % CV in Ka_s produced 59.3 and 42.8 % CV in steady 
state Cs and INR, respectively whereas with 60 % CV in CLint_s produced 163.6 and 
153.6 % CV in steady state Cs and INR, respectively 
3.1.3. Effect of interindividual variability in combined PK parameters: 
After the effect of variability in individual PK parameters was studied separately, 
computer simulations were performed to study the combined effect of interindividual 
variability in CLint_S and Ka_s on steady state Cs and INR. Interindividual variability 
model as shown in Figure 1 c & 1 d were used to facilitate the same amount of variability 
in both the PK parameters at the same time. Table 2 & 3 show the results for the effect of 
interindividual variability in combined PK on the variability in Cs and INR. Figure 2 & 3 
represents the effect of variability in combined PK as the function of % CV in Cs and 
INR, respectively. From Table 2 & 3, and in agreement with the individual parameter 
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( studies, both PK parameters when considered together produced less variability in INR 
than in Cs. Additionally, although the variability in PK parameters when combined 
produced higher amount of variability in Cs and INR than compared to that due to 
variability in individual PK parameters, the combination was less than additive(Figure 2 
& 3). For example, 40% CV in combined PK parameters resulted 71.2 & 74.8 % CV in 
Cs and INR, respectively; 40 % CV in CLint_s resulted 52.2 & 46.5 % CV in Cs and INR, 
respectively; and 40 % CV in Ka_s resulted 40.3 & 28.6 % CV in Cs and INR, 
respectively 
3.2. Variability in PD parameters: 
3.2.1. Effect of interindividual variability in IC50: 
The effect of interindividual variability in IC5o on steady state INR was studied at 6 levels 
of interindividual variability (10, 20, 30, 40, 50 and 60 % CV). Simulation results for 
variability in IC5o when fixed dose of 7 mg warfarin was used are shown in Table 3. 
Figure 3 represents the effect of variability in IC5o as a function of% CV in INR. From 
Figure 3, it can be inferred that there is an approximately linear relationship between the 
variability in ICso and the INR up to 30 % CV. In this range, the variability in INR was 
found to be slightly less than that considered in IC5o. At 40 % or higher variability in 
ICso, the variability in INR was found to be greater than that considered in IC50. For 
example, 20 % CV in ICso produced 14.2 % CV in INR whereas 60 % CV in IC50 
produced approximately 151 % CV, which is 2.5 times the variability of that considered 
in the IC5o. 
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3.2.2. Effect of interindividual variability in Sigmoidicity: 
Simulation studies were carried out with the fixed dose of 7 mg warfarin and the 
variability in Y was translated to variability in INR. The results of these simulations are 
given in Table 3. The relationship between variability in Y and resulting variability in INR 
is shown in Figure 3. Over the entire range of variability studied, the resulting variability 
in INR was found to be much less than that considered in the parameter. For example 
with 60 % CV in the Y, the resulting variability in INR was found to be 1/6 times of that 
considered in Y. However, it is unlikely that this magnitude of variability in INR is 
clinically significant. Comparing the variability curves for IC5o & Yin Figure 3, it can be 
concluded that the INR is less sensitive to the variability in Y than to the variability in 
IC50 or any of the PK parameters studied. 
3.2.3. Effect of interindividual variability in combined PD parameters: 
After the effect of variability in individual PD parameters was studied separately, the 
combined effect of interindividual variability in both IC5o and Yon steady state INR was 
studied at 6 levels of variability (10, 20, 30, 40, 50 and 60 % CV). Proportional error 
model (shown in Figure ld & le) was used to facilitate the same amount of variability in 
both the PD parameters at the same time. The results of these simulation studies are 
shown in Table 3. The relationship between the combined PD variability and the 
variability in INR is shown in Figure 3. Over the entire range of variability studied, the 
relationship between combined PD variability and INR was found to be approximately 
linear up to 30 % CV. In this range except with 10 % CV, the variability in drug response 
was found to be slightly more than that considered in the PD parameters alone. The 
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( variability in INR due to combined PD was found to be greater than the sum of variability 
in INR due to individual PD parameters. At 40 % or greater variability, the drug response 
becomes more sensitive to the changes in PD parameters and we see steep increase in the 
variability curve (Figure 3). For example, with 10 % variability in combined PD, the 
variability in INR was found to be 6.8 % whereas with 60 % CV in combined PD, the 
resulting variability in INR was found to be approximately 2.8 folds of that considered in 
the parameters. The variability in INR was found to be higher due to combined PD than 
that due to combined PK. 
3.3. Effect of combined PK and PD variability: 
Computer simulations were carried to determine the effect of variability in combined PK 
and PD parameters on the drug response. The results of these simulations are given in 
Table 3 and Figure 3. Variability in PK & PD parameters when considered together 
produced higher amount of variability in INR than that produced due to variability in 
individual parameters or combined PK or combined PD parameters, but less than the 
sum of variability in INR due to individual PK & PD parameters. 
There were a number of occasions in which a simulation yielded INR value that was too 
large. Such simulations were terminated and excluded from the study. Essentially with 60 
% CV in combined PK and PD parameters could not be studied because the simulation 
was unsuccessfully terminated due to division by zero or a value that has become too 
large to represent <56>. 
3.4. Variability studies using ANOVA: 
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( The simulation runs were performed as per the experimental design shown in Table 4. 
The distribution of INR values from the simulation runs failed to follow the normality 
assumption (Appendix 1 ). The use of square-root and cubic-root transformations on the 
INR values did not improved the normality. However, a natural logarithmic 
transformation of the INR values greatly improved the normality distribution (Appendix 
2). Therefore, statistical analysis using AVOVA method was performed on the natural 
log transformed data to determine the significance of each parameter and their 
interaction(s). The results of ANOVA test are summarized in Table 5. These results 
indicate that PK parameter (CLint_s) and PD parameter (IC5o) significantly affect the 
variability in INR at level of significance, 0.05. The two-way interaction of PK and PD 
parameters, CLint_s & ICso and CLint_s & Y, were also found to significantly affect INR 
(P<0.05). None of the three-way and four-way interaction(s) of PK and PD parameters 
were found to be significant. Hence, these interactions were combined with error to 
increase the power of the test. Main effects and interaction plots further support the 
results of ANOVA findings. The main effect of a parameter is referred to be the change 
in response produced by a change in the level of the parameter. Figure 4 shows the main 
effects plot for Ln(INR) data. As can be seen from this plot, the level of% CV in CLint_s 
and IC50 seemed to affect the INR values significantly. As the level of the CLint_s 
changed from 30 % CV to 60 % CV, the variation in the mean response value highly 
increased. Similarly in the case of IC5o, as the level is changed from 30 % CV to 60 % 
CV, we see a high increase in the mean response valve. In contrast, the level of% CV in 
Ka_s and Y slightly affect the INR and this effect was minimal. Difference in response 
between the levels of one parameter is not the same at all levels of the other parameter(s). 
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( These differences in the response is referred to be interaction and can be studied using 
interaction plot. Looking at the interaction plot shown in Figure 5, it can be concluded 
that there is an interaction between pairs of various parameters such as CLint_S & IC5o , 
CLint_S & Y and IC5o & Ka_s since the lines for these parameters in the plot are intersecting 
with each other. 
3.5. Effect of intraindividual variability in dose: 
The effect of intraindividual variability in dose on variability in Cs and INR was studied 
at 3 levels (3, 6 and 10 % CV) using both 7 mg and 9 mg dose of warfarin. Sample and 
hold set-up, as shown in Figure lf, was used to cause the dose to change after every 24 
hours. The results of dose variability studies with 7 mg and 9 mg dose of warfarin, are 
shown in Table 6. Figure 6 & 7 show a three-dimensional bar graph of % CV in dose Vs 
% CV in INR with 7 mg and 9 mg doses of warfarin, respectively. Each bar in the Figure 
6 & 7 represent the magnitude of variability in PK/PD response at a given amount of 
variability in the dose. It can be seen in Figure 6 and 7 that variability in dose produced 
approximately equal variability in PK response (Cs). In contrast, the INR appears to be 
less sensitive to changes in the dose since the variability in the dose was associated with 
lower variability in INR. For example, with the maximum variability (10% CV) in 7 mg 
& 9 mg dose resulted 10.06 & 10.38 % CV in Cs and 6.01 & 7.40 % CV in INR, 
respectively. Variability in PK and PD responses were found to increase with the increase 
in the degree of variability in dose. Over the entire range of variability studied, the 
variability in dose produced approximately the same amount of variability in drug's PK 
response and slightly less variability in drug's PD response. For example, with 6 % CV in 
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( 7 mg warfarin essentially resulted 10.06 & 6.01 % CV in Cs and INR, respectively. 
Similarly, with 6 % CV in 9 mg warfarin dose essentially resulted 10.38 & 7.40 % CV in 
Cs and INR, respectively. These differences in PK and PD responses may be attributed to 
their non-linear relationship. 
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( 4. DISCUSSION 
Warfarin, like all the 4-hydroxycoumarin compounds, has an asymmetric carbon atom. 
The clinically available warfarin preparations consists of a racemic mixture of equal 
amounts of two distinct S- and R-enantiomers, the former being 3 to 6 times more potent 
as anticoagulant <34). Hence, variability in warfarin responses most likely arises from 
variability associated with S-enantiomer. Therefore in this study, we have considered 
only the effects of S-enantiomer on warfarin PK and PD responses. 
Warfarin has well established PK-PD relationship, narrow therapeutic range and large 
PK/PD variability making it a ideal candidate to study the impact of various sources of 
variability on the dose-response relationship. In understanding complete dose-response 
relationship for drugs like warfarin, an integrated approach involving combined PK and 
PD modelling has proved tremendously helpful (S, 6• 7)_ Hence, this study has attempted to 
describe the relationships between the PK, the PD and response to warfarin by 
developing an integrated PK-PD model. 
The integrated PK-PD model (Figure la & lb) used in this study is based on individual 
PK and PD models derived from plasma concentration and response data, respectively <6• 
7)_ This model was developed based on the idea that a thorough understanding of the 
impact of variability from a source needed to be based on a complete and integrated PK-
PD model. The model uses additional component to report the anticoagulant response of 
warfarin in terms of INR (Figure 1 b ), which now has globally become the standard way 
of assessing warfarin response <36)_ Previously, there have been no published studies that 
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( have used computer simulations and an integrated PK-PD model to predict the relative 
impact of different sources of variability on warfarin response. Vadher et al. developed a 
computerized PK-PD model of the time course of warfarin action with bayesian 
parameter estimates and used this model to retrospectively predict the daily INR and 
maintenance dose during the initiation of warfarin therapy <57l. 
The operation of integrated PK-PD model in this study was validated by performing the 
run without any variability and evaluating the responses to ensure that they agreed with 
values calculated from basic PK and PD equations. The operation of error models were 
checked by collecting the parameter, which had an error model, and ensuring that the 
variability matched that of the model input. 
Clinically, warfarin experiences a poor correlation between dose and response, primarily 
due to its complex pharmacology and wide inter- and intra-individual variation in dose-
response relationship. Investigations have shown that variation in anticoagulant response 
of warfarin occur due to interindividual variability in hepatic clearance <6• 18• 49• 58l, total 
protein concentration <29l, protein binding affinity <59l, potency (6) and sigmoidicity <6• 7l. In 
this study, a pharmacostatistical model(s) was used to provide theoretical evaluation of 
the relative impact of these sources of variability on warfarin response. 
In the first part of the simulation study, variability was considered in each of the PK and 
PD parameters separately and their relative impact on variability in warfarin response 
was determined. In the second part of the simulation study, variability in combined PK 
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( parameters, combined PD parameters, combined PK and PD parameters were considered 
and their impact on variability in warfarin response was investigated. Finally, the relative 
impact of intraindividual variability in the dose on the variability in the warfarin response 
was studied. 
The simulation studies were conducted using a dose of 7 mg daily since in the PK-PD 
model this dose resulted an INR of 2.2, which is at the lower end of therapeutic range of 
warfarin. This dose is comparitively higher than that used clinically and this is probably 
because the PK and PD parameter values used in this study were derived from healthy, 
young volunteers. And the dose of 9 mg daily gave an INR of 2.7, which is at the upper 
end of the therapeutic range, and was used in the dose variability study because of the 
non-linear PD model. 
PK variability was studied by varymg CLint_S and Ka_S· The value of volume of 
distribution was kept constant throughout the simulation studies because the variability in 
this parameter was reported to be less important <6>. 
CLint_s was studied because it is important parameter that affects clearance and several 
studies have demonstrated clinically significant outcomes when this parameter changes <6• 
18>. As seen in equation 5, clearance which in itself is critical in determining the steady 
state plasma concentration. 
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The variability in CLint_S occurs due to differences in the activity of S-warfarin 
metabolizing enzyme system. There are several well-established PK drug interactions 
with warfarin <60). Many of these drug interactions involve the induction or inhibition of 
the cytochrome P450 enzymes with associated reduced or increased anticoagulant effects, 
respectively. Interaction of warfarin with phenylbutazone and metronidazole results in 
potentiation of anticoagulant effect mainly due to inhibition of the cytochrome P450 
isoform <60). The interaction of warfarin with carbamazepine, phenobarbital, phenytoin 
and rifampin results in decrease of anticoagulant effect because of the enzyme induction. 
William et al. reported marked interindividual differences in the rate of metabolism of 
oral anticoagulants in man <27). Bowles <58) and Gurwitz et al. <61 ) conducted studies to 
determine the effect of age on the anticoagulant response of warfarin and reported that 
elderly people show an exaggerated anticoagulant response to warfarin, possibly because 
of the decrease in clearance with age. 
Chan et al. reported 31 % CV in hepatic clearance of S-warfarin (6). Routledge et al. 
concluded 40 % CV in total clearance of warfarin <18). Based on this information, the 
effect of interindividual variability in CLint_s was studied from 10 to 60 % CV (Figure 3 
& 4). The statistical analysis of computer-simulated data using ANOVA concluded that 
the variability in CLint s alone or in combination with IC5o/Y are significant (P<0.05) and 
need to be carefully considered to perform dose optimization in warfarin therapy and use 
the drug safely. 
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Warfarin is highly protein bound (in excess of 99%) and the anticoagulant effect is 
caused by the very small fraction of the drug that is free. Albumin acts as the storage 
depot for warfarin. As indicated in section 1.5.1 of this thesis, the variation in P and Ka_s 
can occur due to various physiologic and pathologic conditions. Under these 
circumstances clinically significant changes in the anticoagulant response of warfarin 
have been observed <29>. Drugs that can displace the albumin will also in theory increase 
the action of warfarin. However, this effect may be counteracted by more rapid 
elimination of the drug <59>. Interestingly, although variability in protein binding produced 
almost equivalent variability in Cs (Table 2), this source of variability had little impact on 
INR, especially in comparison to variability in CLint_s (Figure 3). The statistical analysis 
of the computer-simulated data using ANOV A indicated that Ka_s do not significantly 
affect the warfarin response (P<0.05). 
The relationship between Cs and PCA is given by (Pitsiu et al 1993) 
PCA = [ 100 I (1 + (C// ICsoy)) ] (16) 
The relationship between the PD parameters and the INR can be derived by subtituting 
the equation (12) and (16) in equation (13): 
INR = (1.001 + (0.355 * C// IC50y) ]1s1 (17) 
Thus, the warfarin response in terms of INR is dependent on PD parameters such as IC50 
and Y. IC50 and Y was reported to vary from individual to individual (6, 1>. Therefore, the 
impact of variability in these PD parameters on INR was studied. 
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Potency (IC50) represents the concentration of drug that produces 50% of the maximum 
effect. It explains the differences in sensitivity of the drug to the receptors. As the IC50 
increases, the drug gets less potent and a smaller response is achieved from a given dose. 
This condition is referred to as warfarin resistance. In contrast as the IC50 decreases, the 
drug gets more potent and a higher response is achieved from a given dose. Such 
condition is usually termed as warfarin sensitivity. In the literature several studies have 
reported about the warfarin resistance and sensitivity. In most cases the exact mechanism 
for these changes has not been identified. However, possible explanations for such 
changes in IC50 of warfarin include altered receptor affinity, noncompliance, exogenous 
consumption of vitamin K, hereditary reasons, laboratory error and concurrent ingestion 
of warfarin with nutritional supplements containing vitamin K are known to decrease 
warfarin's effects. In early 1985, Alving et al reported that 57-year-old black women and 
her family developed warfarin resistance due to hereditary reasons that altered PDs of 
warfarin <43)_ Warfarin resistance associated with infusion of high doses of lipids such as 
propofol containing 10 % soybean oil as an emulsified preparation was investigated by 
MacLaren et al. and concluded that lipid emulsions may interfere pharmacodynamically 
with warfarin activity by enhancing the production of clotting factors, facilitating platelet 
aggregation or may facilitate warfarin binding to albumin <62>. 
The amount of interindividual variability in IC5o was chosen based on the values reported 
in the literature. The population analysis performed by Chan et al. using NONMEM 
approach showed that IC50 of unbound fraction of S-warfarin varied by 58 % CV <6>. In 
this study, the effect of interindividual variability in IC50 on warfarin response was 
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demonstrated from 10 % to 60 % CV (Figure 3). Analysis of the computer-simulated data 
suggests that warfarin response is highly sensitive to variability in ICso alone or in 
combination with CLint_s (Table 5). 
Sigmoidicity refers to the slope value for the relationship between the drug concentration 
and pharmacological effects. Interindividual variability in Y for warfarin is reported in the 
literature (6, 7). It is difficult to explain the reason for the variation in this slope parameter, 
as this parameter has no clear physiological interpretation. However, the variability in Y is 
of substantial clinical significance. Individuals having low Y value (steeper slope) for the 
relationship between drug concentration and the anticoagulant effect will be very 
sensitive to small changes in drug concentration and becomes difficult to maintain their 
INR values in the therapeutic range. On the contrary, individuals with higher Y value for 
drug concentration-effect relationship will not be much sensitive to small changes in drug 
concentration. Chan et al. (6) reported 25 % CV and Pitsiu et al. C7) reported 42 % CV in Y. 
However, this study found that variability in Y, when varied at various levels from 10 % 
to 60 % CV (Figure 3), had little impact on warfarin response. 
Variability in dose results due to weight variation, assay error, flow properties of the 
tablet blend and various formulation processes. The United States Pharmacopoeia allows 
up to 5 % variability in the dose of warfarin <63). Based on this information, the 
intraindividual variability in the dose was studied at three levels (3 , 6 and 10 % CV). 
Variability in the dose resulted in almost the same amount of variability in Cs and 
slightly more than half in INR. Thus, the PK and PD responses appear to be less sensitive 
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to the changes in dose. As seen from Figure 8, it can be concluded that the dose of 
warfarin when used at the lower end and higher end of the therapeutic range does not 
produce significant difference in the PK & PD responses. 
In conclusion, the computer simulations in this study have demonstrated that CLint_S and 
IC50 are most influencing parameters that affect the dose-response relationship than the 
other parameters studied. Therefore, it is important to consider the influence of variability 
in these parameters in optimizing the dose and thereby achieving the desired therapeutic 
effect in patients who have the history of hepatic impairment, warfarin resistance and 
sensitivity. 
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CONCLUSIONS 
• 
• 
• 
• 
• 
An integrated PK-PD model was successfully developed for warfarin usmg 
STELLA® . 
This study demonstrated the importance of considering PD model along with PK 
model to understand the dose-response relationship for warfarin . 
Computer simulations were performed using a pharmacostatistical PK-PD model to 
understand the manner in which various PK and PD parameters affect the dose-
concentration-effect relationship for warfarin. Analysis of simulation data 
demonstrated that interindividual variability in PK parameter (CLint_s) and PD 
parameter (IC5o) most significantly affect the variability in warfarin response. The 
variability in these parameters should be carefully considered in order to use the drug 
safely and effectively . 
Findings from the statistical analysis strongly suggest that CLint_s, IC50 and the 
combination of PK & PD parameters such as CLint_s & ICso and CLint_S & Y 
significantly affect the variability in INR (P < 0.05) . 
The drug response was found to be less sensitive to the intraindividual variability in 
dose and interindividual variability in Ka_s and Y. 
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( Thus, simulation studies usmg STELLA produced sensible results that helps in 
understanding the manner in which the variability in various PK and PD parameters 
affect the overall dose-response relationship. Such information is important and useful in 
optimizing the doses in specific population under risk and uses the drug effectively and 
safely. It is to be noted that the conclusions of this study are obviously limited to the 
theoretical assumptions considered in the model. 
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( Table 1 : Population average values of the PK and PD parameters used in the model 
Parameter Mean Value (Input to Model) * 
PK parameters 
Vd_S 11.8 L 
Vd_R 10.5 L 
CLint_s 59.21 L/h 
CLint_R 32.85 L/h 
Ka_S 300000 h-1 
Ka_R 246600.49 h-1 
PD parameters 
ICso 0.394 
CA_nonnal 100 
y 1.0 
ISI 2.2 
~ 0.094 h-1 
*For sources of these values see the text. 
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( Table 2: Effect of interindividual variability in PK parameters on Cs when 7 mg 
dose of warfarin was used 
% CV in PK % CV in Cs due to variability in [n=lOO] 
parameter 
CLint_s Ka_S Combined PK 
10 10.l 10.3 14.6 
20 20.5 20.6 31.3 
30 32.9 30.5 50.2 
40 52.2 40.3 71.2 
50 120.6 49.8 130.5 
60 163.6 59.3 200.5 
Abbreviations: Clint s =Intrinsic clearance ofS-enantiomer ofwarfarin 
K. s-= Protein binding affinity constant of S-enantiomer of warfarin 
Cp-= Overall warfarin plasma concentration 
Cs = Plasma concentration of S-enantiomer of warfarin 
n =Number of study individuals 
Combined PK= Variability in Cl;01_s and K._s 
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( Table 3: Effect of interindividual variability in PK and PD parameters on INR when 7 mg 
dose of warfarin was used 
%CVin % CV in INR due to variability in [n=lOO] 
PK/PD 
pa ram et 
er 
Clint_S Ka_S Com bi- ICso y Combi- Combined 
nedPK nedPD PK&PD 
10 6.8 7.1 9.0 6.8 1.6 6.2 12.9 
20 14.1 14.3 23.5 14.2 3.2 28.5 31.6 
30 24.4 21.4 42.5 24.5 4.8 48.7 63.7 
40 46.5 28.6 74.8 46.7 6.5 87.5 121.7 
50 119.1 35.7 122.6 117.9 8.2 143.2 157.8 
60 153.6 42.8 161 .2 151.5 10.1 166.l NIA 
Abbreviations: Clint s = Intrinsic clearance of S-enantiomer of warfarin 
K. ; = Protein binding affinity constant of S-enantiomer of warfarin 
IC~0 = Potency of S-enantiomer of warfarin 
Y = Sigmoidicity 
INR = International Normalized Ratio 
n = Number of study individuals 
NIA = Not Applicable 
Combined PK = Variability in Clint s and Ka s 
Combined PD = Variability in IC50-and Y -
Combined PK & PD = Variability in Clint_s , Ka_s, ICso and Y 
44 
( Table 4: Experimental design for ANOVA test 
Run % CV Parameter 
Number CLint_s Ka_S ICso i 
1 - - - -
2 - + - -
3 - - + -
4 - + + -
5 + - - -
6 + + - -
7 + - + -
8 + + + -
9 - - - + 
10 - + - + 
11 - - + + 
12 - + + + 
13 + - - + 
14 + + - + 
15 + - + + 
16 + + + + 
Abbreviations: (-)means 30% CV and(+) means 60% CV 
Cl;01 s = Intrinsic clearance of S-enantiomer of warfarin 
K. 5-= Protein binding affinity constant ofS-enantiomer ofwarfarin 
IC~0 = Plasma concentration of S-warfarin that produces 50% inhibition 
of clotting factor synthesis 
Y = Sigmoidicity 
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Table 5: Analysis of variance of effect of variability in PK and PD parameters on 
Ln(INR) 
Source DF• 
CLint_s 1 
Ka_S 1 
ICso 1 
y 1 
CLint_s*Ka_s 1 
CLint_s*ICso 1 
CLint_s*y 1 
Ka_s*ICso 1 
Ka_s*y 1 
ICso*Y 1 
Error 1495 
Total 1505 
A OF = Degrees of Freedom 
+ Seq SS = Sequential Sum of Squares 
+Adj SS = Adjusted Sum of Squares 
t Adj MS = Adjusted Mean Square 
* p < 0.06 
Seq ss+ Adj ss+ Adj MSt F 
3.2115 2.8096 2.8096 3.41 
0.7613 0.8196 0.8196 1.00 
3.7037 3.4390 3.4390 4.18 
0.1913 0.2329 0.2329 0.28 
0.3629 0.5025 0.5025 0.61 
3.1134 3.2090 3.2090 3.90 
3.2399 3.2149 3.2149 3.91 
0.5449 0.5997 0.5997 0.73 
0.0358 0.0417 0.0417 0.05 
0.0516 0.0517 0.0517 0.06 
1231.2517 1231.2517 0.8236 
1246.4681 
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p * 
0.060 
0.316 
0.041 
0.590 
0.480 
0.049 
0.047 
0.418 
0.832 
0.802 
( Table 6: Effect of intraindividual variability in dose on variability in Cs and JNR. 
% CV in Dose % CV in [n=2000] 
Cs INR 
With Dose 7mg 
3 3.10 1.77 
6 5.93 3.55 
10 10.06 6.01 
With Dose 9mg 
3 2.93 2.21 
6 5.87 4.34 
10 10.38 7.40 
( Abbreviations: CV = Coefficient of Variation 
INR = International Normalized Ratio 
n = Number of study individuals 
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( 
Figure 1: Schematic diagram showing various models in STELLA® 
(a) Pharmacokinetic model 
(b) Pharmacodynamic model 
( c) Interindividual variability in CLint_s 
( d) Interindividual variability in Ka_s 
(e) Interindividual Variability in IC50 
(f) Interindividual variability in Y 
(g) Intraindividual variability in dose 
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Figure 2: Effect of interindividual variability in PK parameters as the function of 
coefficient of variation (CV) in Cs when 7 mg dose ofwarfarin was used. 
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Figure 4: Main effects plot ofLn(INR) data. 
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Figure 5: Interaction plot of Ln(INR) data. 
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Figure 6: Effect of intraindividual variability in dose (7 mg) as the function of coefficient 
of variation (CV) in Cs and INR. 
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Figure 7: Effect of intraindividual variability in dose (9 mg) as the function of coefficient 
of variation (CV) in Cs and INR. 
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Figure 8: Effect of intraindividual variability in dose as the function of coefficient of 
variation (CV) in INR with dose of 7 mg and 9 mg warfarin. 
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Appendix 1: Model adequacy check for INR data using ANOV A test. 
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Appendix 2: Model adequacy check for Ln(INR) data using ANOV A test. 
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